VRNA
Verona Pharma
VRNA
VRNA
Delisted
VRNA was delisted on the 6th of October, 2025.
88 hedge funds and large institutions have $1.31B invested in Verona Pharma in 2022 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 24 increasing their positions, 25 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
88
Holders Change
+20
Holders Change %
+29.41%
% of All Funds
1.42%
Holding in Top 10
16
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+128.57%
% of All Funds
0.26%
New
32
Increased
24
Reduced
25
Closed
10
Calls
$29.8M
Puts
$6.29M
Net Calls
+$23.5M
Net Calls Change
+$19.9M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$46M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$29.9M |
| 3 |
Jennison Associates
New York
|
+$26.9M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$18.7M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$9.43M |
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$29.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$21.7M |
| 3 |
State Street
Boston,
Massachusetts
|
-$11.4M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.14M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.11M |
